Summary & Overview
HCPCS J7323: Euflexxa, Intra-articular Hyaluronan Injection
HCPCS Level II code J7323 denotes a single dose of hyaluronan derivative branded as Euflexxa for intra-articular injection, commonly used for viscosupplementation of the knee. This code is nationally relevant because intra-articular hyaluronan products are frequently billed across outpatient settings and influence utilization patterns, coverage determinations, and pharmacy-management policies for joint pain therapies.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise national overview of coverage landscapes, common billing and coding considerations, and payer-specific payment practices where available. The publication summarizes benchmarks for use of J7323, highlights clinical context for viscosupplementation in joint care, and notes recent policy clarifications that affect billing and authorization workflows.
This report is intended for billing managers, revenue cycle leaders, and clinicians involved in musculoskeletal care who need a clear reference on how J7323 is defined, where it is typically administered, and which major payers are central to coverage and payment decisions. Data not available in the input will be identified as such in relevant sections.
Billing Code Overview
HCPCS Level II code J7323 represents hyaluronan or derivative, euflexxa, for intra-articular injection, per dose. This code covers the pharmaceutical product administered as an intra-articular injection intended to provide viscosupplementation for joint spaces, typically the knee.
Service Type: Intra-articular injectable (viscosupplementation)
Typical Site of Service: Outpatient clinic, physician office, or ambulatory surgery center for intra-articular joint injection
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with symptomatic osteoarthritis of the knee presents to an orthopedic clinic after conservative measures (nonsteroidal anti-inflammatory drugs, activity modification, physical therapy) provided limited relief. The patient reports persistent joint pain, stiffness, and intermittent swelling affecting activities of daily living. After clinical evaluation and review of prior imaging demonstrating moderate tricompartmental osteoarthritic changes, the treating orthopedic surgeon discusses intra-articular viscosupplementation with a hyaluronan derivative. On the day of service the patient is positioned supine, the knee is prepped using standard sterile technique, local anesthetic is administered to the skin and subcutaneous tissues, and the clinician performs an intra-articular injection of J7323 (euflexxa), single dose. The clinical workflow includes verification of laterality (right or left), documentation of informed consent, allergy review, indication (osteoarthritis of the knee), number of prior injections and response, injection technique, amount injected, lot number of product, and post-procedure observation. Typical site of service is an outpatient clinic, orthopedic office, or ambulatory surgical center. Billing uses the HCPCS Level II code J7323 for each dose administered; documentation must support medical necessity and correlate with the associated ICD-10 diagnosis for coverage determination. Post-injection instructions and follow-up plan are documented, and any immediate complications (eg, allergic reaction, infection) are recorded and managed according to office protocols.
Coding Specifications
| Modifier | Description | When to Use |
|---|